AffyImmune Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States2-10 Employees

AffyImmune Therapeutics is a clinical-stage biotechnology company developing CAR T cell therapies for solid tumors, using its Tune & Track platform to optimize T cells. Founded in 2016 and based at 22 Strathmore Road in Natick, Massachusetts, the company operates with a small workforce of 2 to 10 employees in the biotechnology research sector. Its lead product candidate, AIC100, uses affinity tuning to spare healthy cells, aiming to improve safety and efficacy, with an initial indication in refractory thyroid cancer and an antigen that is overexpressed in other cancers, including stomach cancer and triple-negative breast cancer. The company notes ongoing CAR T cell therapy development in solid tumors and has pursued leadership and governance changes in 2024, including the appointment of a Chief Medical Officer and new members to the Board of Directors. Public disclosures also indicate funding of about $20 million and revenue in the range of $0 to $1 million.

Get verified AffyImmune Therapeutics emails free

Company overview Employee directory